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Recently,therehavebeenadvancesinthedevelopmentofnewsubstanceseﬀectiveinmanagingdiabeticdisorders.Opioidreceptors
couple multiple systems to result in various biological eﬀects, although opioids are best known for analgesia. In the present review,
we used our recent data to describe the advance in plasma glucose-lowering action of herbal products, especially the mediation of
β-endorphin in glucose homeostasis of insulin-deﬁcient diabetes. In type 1-like streptozotocin-induced diabetic rats, we identiﬁed
manyproductspuriﬁedfromherbsthatshowadose-dependentplasmaglucose-loweringaction.Increaseinβ-endorphinsecretion
fromtheadrenalglandmayactivateperipheralopioidμ-receptors(MOR)toenhancetheexpressionofmuscleglucosetransporters
and/or to reduce hepatic gluconeogenesis at the gene level, thereby leading to improved glucose utilization in peripheral tissues
for amelioration of severe hyperglycemia. It has also been observed that stimulation of α1-adrenoceptors (α1-ARs) in the adrenal
gland by some herbal products is responsible for the increase in β-endorphin secretion via a phospholipase C-protein kinase
dependent pathway. However, an increase in β-endorphin secretion from the adrenal gland by herbal products can function via
another receptor. New insights into the mediation of endogenous β-endorphin activation of peripheral MOR by herbal products
for regulation of glucose homeostasis without the presence of insulin have been established. Therefore, an increase in β-endorphin
secretion and/or direct stimulation of peripheral MOR via an insulin-independent action might serve as the potential target for
development of a therapeutic agent or promising adjuvant in intensive plasma glucose control.
1.Introduction
Diabetes mellitus, which ranks among the top 10 causes of
mortality in the world, is a metabolic disease characterized
by abnormally high levels of glucose in the blood and/or
urine. This metabolic disorder often leads to disability from
vascular complications, including coronary artery disease,
cerebrovascular disorder, renal failure, blindness and limb
amputation, in addition to neurologic complications and
premature death [1]. In order to normalize the plasma
glucose level, dietary restrictions, exercise and oral glucose-
lowering agents are widely used [2].
A widely recommended approach for the control of
hyperglycemia is to administer a parenteral insulin prepara-
tion that provides a constant addition of circulating insulin
for 12–24h to augment or replace the deﬁcient endogenous
insulin secretion [3, 4], although insulin resistance is initially
recognized in insulin-treated patients. Like other hormone-
sensitivepathways,theintracellularpathwayofinsulinaction
is continuously being regulated by multiple inﬂuences. Con-
tinuousexposuretoinsulincausesareductioninthenumber
of receptors on the cell surface by promoting internalization
as well as degradation of hormone-occupied receptors [5].
The insulin receptor is linked with tyrosine kinase that acti-
vates itself and then transmits its stimulatory message after
the phosphorylation of selected tyrosine. During continuous
exposure to insulin, the kinase activity of the receptor is
diminished as a result of combined eﬀects of various factors
[6–8]. Also, chronic exposure of the cell to insulin may result
in a diminished concentration of downstream elements,
including insulin receptor substrate proteins [8]. The mech-
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induction of insulin resistance are complex and incompletely
deﬁned. Thus, it is imperative to provide new targets
achieving equal and/or superior eﬀects on insulin to control
glycemia with less insulin resistance.
Opioid receptors are coupled to multiple systems and
play a role in various biological eﬀects, including analgesia,
miosis, bradycardia, general sedation, hypothermia, insen-
sitivity and depression of ﬂexor reﬂexes [9]. Opiods have
a well-known role in lowering pain [10], in addition to
modulation of the immune system and endocrine processes
[11]. The peripheral eﬀect of opiates on glucose homeostasis
through pancreatic islet hormone secretion has also been
documented [12, 13]. The opioid peptide, β-endorphin, has
been shown to regulate insulin, glucagon, and somatostatin
release from isolated Langerhans islets [14–16]. In addition
to the ﬁnding that β-endorphin can inhibit glucose produc-
tioninconsciousdogs,β-endorphinhasanabilitytoincrease
insulin secretion via activation of opioid receptors located
in pancreatic β-cells [17, 18]. From the eﬀect of opioids on
glucose homeostasis, opioids or opioid receptor activation
may have merit in glycemic control. However, the eﬀect of
opioids on glucose metabolism in the absence of insulin
remains obscure.
Recently, we provided a new evidence that activation of
peripheral opioid μ-receptors (MOR) might modify glucose
metabolism-associated genes to improve glucose utilization
and reduce hepatic gluconeogenesis, thus leading to a
decrease in high plasma glucose in streptozotocin-induced
diabetic rats (STZ-diabetic rats). The deﬁcient function of
pancreatic β-cells in STZ-diabetic rats has been documented
and rats with STZ-induced diabetes are widely used as an
animal model of type 1-like diabetes [19]. The eﬀect of
opioids on glucose homeostasis in type 1-like diabetic rats
may in fact be produced by mechanisms other than insulin.
Currently, there is an enormous increase in the application
of herbal and other alternative medicines for the treatment
of diabetic disorders. Thus, chemical compounds or herbal
products with the ability to enhance β-endorphin secretion
and/or peripheral MOR activation, but not an opiate-like
central nervous eﬀect, might be valuable as a therapeutic
intervention or an attractive adjuvant for diabetic disorders.
Herein, we describe recent advances in insulin-independent
mechanism(s) of herbal products in the management of
glucose metabolism in insulin-deﬁcient diabetes.
2. Endogenousβ-Endorphin Participatesin
the Plasma Glucose-LoweringAction inan
Insulin-DeﬁcientState
2.1. Roles of Endogenous Opioids on Glucose Homeostasis.
Previous studies have demonstrated that diﬀerent forms
of stress activate the endogenous opioid system, which in
turn contributes to the changes in systemic cardiovascular
function and endocrine responses occurring under these
conditions [20–22]. Exposure to a cold environment may
increase sympathetic nervous activity, inducing an elevation
of plasma norepinephrine (NE) and result in hyperglycemia
[23]. However, in STZ-diabetic rats, the plasma glucose-
lowering response is observed after cold exposure at 4◦Cf o r
1h with an elevation of β-endorphin-like immnoreactivity
(BER) in plasma, which does not occur in normal rats
[24]. The decrease in plasma glucose and increase of BER
in response to cold stress are blocked by prazosin at a
dose suﬃcient to abolish α1-adrenoceptors (ARs) activity.
Also, the lowering of plasma glucose in STZ-diabetic rats
by cold stress is abolished in the presence of a naloxone
dose suﬃcient to block opioid receptors. Opioid receptor
activation thus appears to be related to the plasma glucose-
lowering action of cold stress in STZ-diabetic rats.
Although many physiologic actions of endogenous β-
endorphinarerecognizedtobemediatedbyMOR,including
the regulation of plasma glucose [25, 26], mediation of
opioid δ-receptors (located on skeletal muscles) in the hypo-
glycemic eﬀect of BER has been demonstrated [27–29]. We
used MOR knockout mice to verify that MOR are involved
in the regulation of plasma glucose in the absence of insulin
[30]; the plasma glucose-lowering response to cold stress
was not present in STZ-diabetic mice lacking MOR. Also,
exogenous β-endorphin induced plasma glucose-lowering
activity was abolished in MOR knockout STZ-diabetic mice
[30]. Therefore, activation of MOR appears to be responsible
for the plasma glucose-lowering response to cold stress in
insulin-deﬁcient diabetic animals.
2.2. Activation of α-ARs in the Adrenal Medulla Enhance β-
Endorphin Secretion in an Insulin-Deﬁcient State. Although
β-endorphin is released along with adrenocorticotrophic
hormone from the pituitary gland [31], the presence of
endogenous opioids in the adrenal medulla has been identi-
ﬁedinseveralspecies[32–35].Variousformsofpolypeptides
that cross-react with opioid antisera are stored together
with catecholamines and soluble proteins in the granules
of the adrenal gland. Bilateral adrenalectomy abolishes the
plasma glucose-lowering response to cold stress in type 1-
like diabetic animals [30]. Therefore, activation of MOR by
opioids from the adrenal gland appears to be responsible
for the plasma glucose-lowering response to cold stress in
diabetic animals with insulin deﬁciency.
The binding site of α1-ARs in theadrenal medulla has
been observed [36]. We have demonstrated that pharma-
cologic manipulation with methoxamine, an agonist of α1-
ARs, reduced plasma glucose along with an elevation of
plasma BER in STZ-diabetic rats, but a similar elevation
of plasma BER by methoxamine has not been observed in
normal rats [24]. A dose-dependent increase in plasma NE
and β-endorphin has been demonstrated in STZ-diabetic
rats receiving prostaglandin (PG)E2 injections, and these
PGE2-induced actions are blocked by prazosin at a dose
suﬃcient to abolish α1-ARs eﬀects [37]. We also observed
that phenylephrine enhances BER secretion from isolated
adrenal medulla of Wistar rats in a concentration-dependent
manner and this action is abolished by prazosin [38].
Secretion of β-endorphin from the adrenal glands of insulin-
deﬁcient hyperglycemic rats in response to α1-ARs activation
is further supported by the ﬁnding that the plasma glucose-
lowering action of PGE2 is deleted in STZ-diabetic rats
undergoing bilateral adrenalectomy and no increase in
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of PGE2 [37]. Activation of α1-ARs in the adrenal medulla
for the regulation of endogenous opioid secretion should
thus be considered. Indeed, our data support that pituitary
gland-independent release of endogenous opioids is exists in
peripheral organs [39–41].
2.3. Signals for the Increase of β-Endorphin Secretion after
Activationofα-ARsintheAdrenalMedulla. Ithasbeenestab-
lished that α1-ARs belong to the family of G protein-coupled
receptors which initiate signals by activating phospholipase
C (PLC)-dependent hydrolysis of phisphatidylinositol 4,5
biphosphate [41, 42]. This enzyme may generate the second
messengers, inositol-1,4,5-triphosphate (which releases Ca2+
from intracellular stores) and diacylglycerol (DAG; which
synergizes with Ca2+ to activate protein kinase C (PKC)
[41, 42]. U73122, an aminosteroid derivative, has widely
been used as a speciﬁc inhibitor of PLC [43]. After com-
parison with its negative control, U73343 [44], the response
sensitive to this inhibitor can be identiﬁed as an activation
of membrane-bound PLC. It has been demonstrated that
U73122 abolishes phenylephrine-stimulated BER secretion
from the rat adrenal medulla, but U73343, the negative
control, failed to modify this action of phenylephrine [38].
The role of PKC in the increase of BER secretion by α1-
ARs in the rat adrenal medulla has also been characterized
by using chelerythrine [45] and GF 109203X [46]b e c a u s e
both compounds inhibit PKC in a competitive manner
with respect to the phosphate acceptor. Indeed, the action
of phenylephrine to stimulate BER secretion from isolated
rat adrenal medulla is attenuated by chelerythrine or GF
109203X in a concentration-dependent manner. This survey
showed the involvement of the PLC-PKC pathway in the
activation of α1-ARs related to the higher secretion of β-
endorphin from the adrenal gland.
Multiple subtypes of α1-ARs have been characterized
and the receptor is classiﬁed into three native subtypes
(α1A, α1B and α1D) with corresponding cloned counterparts
(α1a, α1b and α1d)[ 47–51]. It has been demonstrated that
phenylephrine-stimulated β-endorphin secretion in isolated
rat adrenal medulla is attenuated by pretreatment with
tamsulosin [38]. Although tamsulosin acts on both α1A-AR
and α1D-AR, this compound is more selective for the α1A-
subtype [52]. Thus, activation of α1-ARs, especially the α1A-
subtype, on the adrenal medulla of insulin-deﬁcient animals,
may enhance the secretion of endogenous β-endorphin to
regulate plasma glucose homeostasis. However, the subtype
of α1-ARs presenting in the adrenal medulla has not been
clearly identiﬁed and requires clariﬁcation.
2.4. Higher β-Endorphin Biosynthesis in the Adrenal Gland
under an Insulin-Deﬁcient State. Pro-opiomelanocortin
(POMC), the precursor to β-endorphin and several other
peptides, is synthesized by the following two groups of
central neurons: (i) the arcuate nucleus and adjacent
regions of the medial basal hypothalamus and (ii) the
commissural subnucleus of the nucleus tractus solitarius
[53]. The presence of endogenous opioids in the adrenal
gland has been identiﬁed in several species [32, 34, 35, 54].
We observed that POMC gene expression is elevated, which
is related to an increase of β-endorphin in the adrenal
glands, resulting in higher plasma BER in STZ-diabetic rats
as compared to normal rats [55]. Otherwise, a decrease in
POMC mRNA level has been reported in the pituitary, but
no change in the whole hypothalamus of diabetic rats [56].
In contrast, an increase in POMC mRNA level in the thymus
is evident in STZ-diabetic rats, while gene expression of
POMC in the spleen is unaltered [57]. This may be due to
tissue diﬀerence. Nevertheless, an increase of β-endorphin
synthesis in insulin-deﬁcient diabetic rats supports a higher
response to activate the opioid system for lowering plasma
glucose.
3. Peripheral MOR Activation
Participatesinthe Plasma Glucose-Lowering
Action in an Insulin-Deﬁcient State
3.1.IncreaseofPeripheralMORGeneExpressioninanInsulin-
Deﬁcient State. In our previous study, a dose-dependent
lowering of plasma glucose was observed in the fasting STZ-
diabetic rat 15min after intravenous injection of exogenous
β-endorphin; this action was abolished by pretreatment
with naloxone or naloxonazine at doses suﬃcient to block
MOR [58]. Also, agonists of MOR, including loperamide
and tramadol, lower plasma glucose in STZ-diabetic rats,
and this action was neutralized by MOR blockade [59, 60].
In contrast, the MOR activation-induced plasma glucose-
loweringeﬀectwasnoteasytoobtaininanimalswithnormal
insulin action. It seems that a higher response to MOR acti-
vation might be responsible in diabetic rats lacking insulin.
Many studies have indicated that diabetes or hyperglycaemia
alter the sensitivity of animals to various agents [61, 62]. It
has also been demonstrated that diabetic animals are more
sensitive than normal controls to the hyperphagic eﬀect of
agonists speciﬁc to MOR [63]. However, diabetic animals
are less sensitive than normal controls to anti-nociceptive
action mediated by supraspinal MOR [64, 65]. In addition
to the parameter of neuropathy in diabetic disorders [66],
this may be due to the diﬀerence between the central nervous
system and peripheral tissues, while little information is
available regarding the change of MOR in diabetic disorders.
It has been shown that the expression of β-endorphin action
receptor on skeletal muscle is vastly increased in type 1
and type 2 diabetic animals [67, 68]. Our previous reports
indicatedthatanincreaseinMORnotonlyexistedinskeletal
muscle, but the higher protein level of this receptor was also
observed in the liver of STZ-diabetic rats [69]. Therefore,
both the amount of opioid and the gene expression of MOR
were raised in STZ-diabetic rats.
3.2. Activation of Peripheral MOR Enhances an Increase of
Glucose Utilization under an Insulin-Deﬁcient State. Using
the intravenous glucose challenge test (IVGCT) that is
available to characterize the ability of animals to clear
glucose from the circulation, we observed that an intra-
venous injection of loperamide at a dose which activates
MOR (17.6μgkg −1) signiﬁcantly attenuates the increase of
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[59]. Activation of peripheral MOR may increase glucose
utilization to ameliorate hyperglycemia under the absence of
insulin should be considered.
Glucose uptake or transportation depending on insulin-
stimulated translocation of glucose carriers to the cell
membrane belongs to the rate-limiting step in carbohydrate
metabolism of skeletal muscle, a major site for glucose
disposal [70]. Under basal conditions, the rate of glucose
uptake into skeletal muscle is low and insulin-stimulated
glucose disposal is believed to be the major regulation of
plasma glucose concentration [70]. Hyperglycemia is an
abnormal metabolic state characterized by a marked insulin
defect in muscle [71]. We demonstrated that β-endorphin
causes an increase in glucose uptake in isolated soleus
muscles of STZ-diabetic rats to lower plasma glucose and
this eﬀect is antagonized by MOR-speciﬁc blockers [58]. The
stimulatory eﬀects of loperamide and tramadol on glucose
uptake have also been shown in soleus muscles isolated from
STZ-diabetic rats and the eﬀects are blocked by an inhibitor
speciﬁc to MOR [60, 72]. Thus, activation of peripheral
MOR results in an increase in glucose uptake into skeletal
muscle and is related to the lowering of plasma glucose
under an insulin-deﬁcient state.
The liver is also responsible for the regulation of blood
glucose through its ability to store glucose as glycogen
and/or to produce glucose from glycogen breakdown or
gluconeogenic precursors [73]. In diabetes, elevation of
blood glucose is a consequence of increased hepatic glucose
output together with reduced peripheral glucose utilization
[74]. We have observed that both naloxone and naloxon-
azine, at concentrations suﬃcient to block MOR, inhibit the
increase in glycogen synthesis in STZ-diabetic rats [58, 60,
72]. Therefore, an increase in glucose utilization through
peripheral MOR activation can be considered as one of
the mechanism(s) for regulation of plasma glucose in the
absence of insulin.
3.3. Signals for the Increase in Glucose Uptake by Periph-
eral MOR Activation. Opioid receptor activation couples a
number of intracellular signaling pathways, including the
mediation of PLC and PKC activation [75]. The uptake of
radioactive glucose into isolated soleus muscle induced by
β-endorphin is abolished by U73312, the speciﬁc inhibitor
of PLC, while it is not aﬀected by U73343, the negative
control of U73312 [58]. Moreover, chelerythrine and GF
109203X diminished the stimulatory eﬀect of β-endorphin
on radioactive glucose uptake into isolated soleus muscle at
a concentration suﬃcient to inhibit PKC [58]. The linkage
of MOR and the PLC-PKC pathway in the regulation of
glucose uptake is further characterized using the blockade
of loperamide-stimulated 2-DG uptake in C2C12 cells by the
inhibitorsspeciﬁcforPLCorPKC[76].Thedatasuggestthat
activationofMORmayincreaseglucoseuptakeinperipheral
tissues via the PLC-PKC pathway to lower plasma glucose in
diabetic rats lacking insulin.
A family of glucose transporters (GLUT) mediates glu-
cose transport across the cell membrane, while the subtype
4 form (GLUT 4) is predominant in skeletal muscle [77].
Reduction in insulin-mediated glucose uptake caused by
lower gene expression of GLUT 4 in diabetes has been
observed [71, 78]. It has been reported that PKC is involved
in the rate-limiting step in GLUT gene expression [79]. The
gene expression of GLUT 4 in soleus muscles of STZ-diabetic
rats is increased by loperamide after repeated injection for
3d a y s[ 72]. Activation of MOR by tramadol to increase
glucose uptake into isolated soleus muscles with an elevation
ofGLUT4geneexpressioninSTZ-diabeticratshasalsobeen
observed [60]. Therefore, the PLC-PKC pathway is linked to
peripheral MOR activation for regulation of muscle GLUT 4
gene expression.
3.4. Decrease of Hepatic Gluconeogenesis by Peripheral MOR
Activation in Insulin-Deﬁcient State. Phosphoenolpyruvate
carboxykinase (PEPCK; EC 4.1.1.32), the main catalyzing
enzyme in gluconeogenesis, has widely been studied in hep-
atic carbohydrate metabolism [80, 81]. Studies in diabetic
animals have shown that augmented gluconeogenesis is a
major factor in the increase in plasma glucose that appears
in fasting and post-absorptive states [74]. Downregulation
of the PEPCK gene might be associated with a decrease in
hepatic gluconeogenesis to result in the lowering of plasma
glucose. We observed that loperamide at the dose which is
eﬀective in activating MOR, decreased the plasma glucose
of STZ-diabetic rats accompanied by a marked reduction
of PEPCK gene expression in the liver [72]. Similarly, an
increased expression of the hepatic PEPCK gene in STZ-
d i a b e t i cr a t si sr e v e r s e db yt r a m a d o l[ 60]. Thus, peripheral
MORactivationmightactasanegativeregulatortoinﬂuence
hepatic PEPCK gene expression and ameliorate the severe
hyperglycemia in animals with insulin insuﬃciency. Gene
expression of hepatic PEPCK is regulated by a number of
hormones [81, 82], but signals for insulin to inhibit PEPCK
expression are not transmitted through the PKC pathway
[82]. Nevertheless, the decline in hepatic gluconeogenesis for
lowering of plasma glucose mediated by peripheral MOR
activation in the absence of insulin has been established.
4. Mediationof Endogenous β-Endorphin in
the Plasma Glucose-Lowering Action of
Herbal Products
4.1. Herbal Products Directly Activate αA-ARs on Adrenal
Glands to Increase β-Endorphin Secretion. Modern medicine
is believed to be the best treatment approach for acute
conditions. However, Traditional Chinese medicine (TCM)
is based on natural plants and such comprehensive and
ﬂexible treatment strategies always bring about fantastic
treatment results. Recently, for the treatment of chronic
conditions, most modern people prefer green and safe
medicine and this tendency is becoming more and more
prominent. Thus, people in the world are interested in
TCM and it is gradually becoming mainstream medicine.
Currently, there is an enormous increase in the application
of herbs and other alternative medicines for the treatment
of diabetic disorders. However, the mechanisms for these
treatments remain unclear. Based on our previous studies,Evidence-Based Complementary and Alternative Medicine 5
Table 1: Herbal products exert plasma glucose-lowering action via β-endorphin secretion or activation of peripheral MOR in type 1-like
diabetic animals
Herbal products Chemical names Insulin-independent plasma glucose-lowering
mechanisms
Caﬀeic acid 3,4-Dihydroxycinnamic acid [83–85]
Activation of α1-ARs on adrenal glands to increase
β-endorphin secretion; the released β-endorphin
then stimulates peripheral MOR leading to enhance
glucose uptake and attenuate hepatic
gluconeogenesis
Isoferulic acid 3-Hydroxy-4-methoxycinnamic acid [86–89]
Puerarin 4 ,7-Dihydroxy-8-C-glucosylisoﬂavone [90–92]
Andrographolide 2.4.5.7-Trihydroxyﬂavone [93–95]
Myricetin 3,3 ,4 ,5,5 ,7-Hexahydroxyﬂavone [96, 97]
The insulin-independent plasma glucose-lowering
action of these compounds was induced by
activation of peripheral MOR via released
β-endorphin, while the receptor mediated on the
enhancement of adrenal β-endorphin secretion is
still unclear.
Ginsenoside Rh2 Proto-panaxadiol-3-o-β-d-glucopyranoside [98]
Syringin 4-(3-hydroxy-1-propenyl)-2,6-dimethoxyphenyl
[99, 100]
here, we indicated that some herbal products possess the
plasma glucose-lowering property mediated by β-endorphin
in the absence of insulin.
Hydroxycinnamic acids, such as caﬀeic acid (3,4-dihyd-
roxycinnamic acid), ferulic, acid (4-hydroxy-3-methoxycin-
namic acid) and isoferulic acid (3-hydroxy-4-methoxyci-
nnamic acid) (Table 1) are present in a large variety of fruits
and vegetables, including blueberries, grapes, apples, cereal
bran, broccoli, spinach and lettuce [101]. Hydroxycinnamic
acid derivatives have been reported to show numerous
biological activities, such as antioxidant activity, suppression
of interleukin-8 production, interaction with oxytocin,
inhibition of 5-lipoxygenase, eﬀect on the arachidonic acid
cascade, and anti-inﬂammatory activity [102–105]. The
potential eﬀect of hydroxycinnamic acid derivatives on
glucose metabolism in insulin-deﬁcient rats has also been
demonstrated; activation of α1A-ARs in adrenal medulla by
caﬀeic acid [83–85] and isoferulic acid [86–89] enhance the
secretion of β-endorphin from the adrenal glands of STZ-
diabetic rats (Table 1, Figure 1). Thus, hydroxycinnamic acid
derivatives might serve as adjuvants for amelioration of high
plasma glucose in patients with diabetes.
Traditionally, puerarin, a naturally occurring isoﬂavone
C-glycoside, is used to reduce febrile symptoms, dilate arte-
rial coronary and cerebral vessels, and decrease myocardial
consumption of oxygen [106–109]. In addition, andro-
grapholide belongs to the diterpene lactones, and has been
reported to have multiple pharmacologic properties, such
as protozoacidal activity, inhibition of platelet aggregation,
inhibition of protein convertases-1 and -7, and furin, stim-
ulation of cell diﬀerentiation, and anti-hepatotoxic activity,
and may be developed as the drug for treatment of tissue
injury, septic shock, and autoimmune diseases [110–115].
We found that puerarin [90–92] and andrographolide [93–
95] also posses the ability to activate α1-ARs, especially
the α1A-subtype, to enhance β-endorphin secretion from
adrenal glands of STZ-diabetic rats (Table 1, Figure 1). Thus,
these compounds possess plasma glucose-lowering property
without insulin.
4.2. Other Herbal Products with the Ability to Increase β-
Endorphin Secretion. An increase in β-endorphin secretion
by herbal products does not depend on activation of α1-
ARs only. The plasma glucose-lowering action of myricetin,
a naturally occurring ﬂavonoid, is commonly found in tea,
berries, fruits, vegetables and the medicinal herb, mediated
byactivationofα1-ARstoincreasethereleaseofβ-endorphin
in type 1-like diabetic rats is not be deﬁned [96, 97].
Althoughmediationofβ-endorphinbyginsenosideRh2,one
of the ginsenosides contained in Panax ginseng root, or by
syringinofEleutherococcussenticosustolowerplasmaglucose
in STZ-diabetic rats have been demonstrated, the mediated
receptors of the compounds remain to be identiﬁed [98–
100]. Therefore, the insulin-independent plasma glucose-
lowering action of herbal products is not simple and needs
more investigations.
5. Conclusions
Taken together, the ﬁndings of our study provide new
insight into the roles of both α1-ARs and MOR in glucose
homeostasis in insulin-deﬁcient diabetes. In the adrenal
gland,α1-ARsactivationmayincreaseβ-endorphinsecretion
via the PLC-PKC pathway, which in turn activates peripheral
MOR to modify gene expression associated with glucose
metabolism, including muscle GLUT 4 and hepatic PEPCK,
thereby leading to improved peripheral glucose utilization
and decreased hepatic gluconeogenesis for amelioration of
severehyperglycemiaintype1-likediabetes(Figure 1).Thus,
chemical compounds or herbal products that could enhance6 Evidence-Based Complementary and Alternative Medicine
• Caﬀeic acid
• Isoferulic acid
• Puerarin
• Andrographolide
⊕
α1-AR
PLC-PKC dependent
Adrenal gland
• Myricetin
• Ginsenoside Rh2
• Syringin
⊕
⊕
β-endorphin ↑
⊕
MOR
MOR
PLC-PKC dependent
GLUT 4 expression ↑
Glucose uptake ↑
Skeletal
muscle
Glucose utilization ↑
Hepatic gluconeogenesis ↓
Hyperglycemia ↓
Liver
PEPCK expression ↓
Glycogen synthesis ↑
Figure 1: The possible mechanisms of herbal products on the plasma glucose-lowering action are mediated by activation of adrenal α1-ARs
and/or stimulation of peripheral MOR in the absence of insulin. Activation of α1-ARs to increase β-endorphin release from adrenal gland
was involved in the insulin-independent plasma glucose-lowering action of caﬀeic acid, isoferulic acid, puerarin and andrographolide. The
receptor mediated on the adrenal β-endorphin secretion induced by myricetin, ginsenoside Rh2 and syringin is not clear, but the insulin-
independent plasma glucose-lowering activity of these compounds were induced by activation of peripheral MOR via released β-endorphin.
β-endorphin secretion and/or stimulate peripheral MOR
might serve as a potential agent or an attractive adjuvant for
targeting plasma glucose control without insulin. However,
this result seems related to the absence of insulin and
is diﬀerent with the changes in normal animals. Also,
mediation of other opioid peptides in the activation of
peripheral MOR for plasma glucose-lowering actions in
diabetic animal cannot be ruled out.
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